Hiring Women Execs in Biotech, VC Firms Is a Moneyball Play (Part 2)  

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.